Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
A 2024 study published in JAMA Ophthalmology reported that patients with Type 2 diabetes who took semaglutide-containing medications had more than a fourfold higher risk for developing non-arteritic anterior ischemic optic neuropathy (NAION) compared with patients not on a GLP-1 agonist
Plaintiffs argue that manufacturers knew, or should have known, of the full scope of these risks based on c linical data , adverse event reports, and post-market surveillance, yet failed to provide clear, timely warnings to physicians and patients
But individual response varies based on baseline glutathione status, genetic polymorphisms in glutathione synthesis enzymes, and concurrent medications that affect redox balance
Each plan is designed with safety, comfort, and long-lasting results in mind
